LifeStance Health Group (LFST) Earnings Analysis
LifeStance Health Group (LFST) next reports earnings on 2026-08-06, consensus EPS 0.02 USD. Last quarter (2026-05-07) it beat with EPS 0.04 USD vs 0.01 USD est (+300%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E 182.89.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does LFST next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 0.02 USD |
| Revenue estimate | 0.41B |
LFST earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | 0.04 USD | 0.01 USD | +300% | Beat |
| 2026-02-25 | 0.03 USD | -0.00094 USD | +3291.5% | Beat |
| 2025-11-06 | 0.00277 USD | -0.01 USD | +127.7% | Beat |
| 2025-08-07 | -0.01 USD | -0.03 USD | +66.7% | Beat |
| 2025-02-27 | -0.02 USD | -0.04 USD | +50% | Beat |
Beat rate: 5/5 (100%) over reported quarters with consensus data.
LFST valuation and analyst view
| Trailing P/E | 182.89 |
|---|---|
| Trailing EPS | 0.0599 USD |
| Price / book | 2.89 |
| Dividend yield | 0.00% |
| Market cap | 4.29B |
| Analyst consensus | Buy (9 buy / 2 hold / 0 sell) |
| Avg price target | 11.8 USD |
Related research pages
Frequently asked questions
When is LifeStance Health Group (LFST)'s next earnings date?
LifeStance Health Group is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.02 USD and revenue estimate of 0.41B.
Did LFST beat earnings last quarter?
In its 2026-05-07 report, LFST posted EPS of 0.04 USD versus a 0.01 USD estimate — a beat of 300%.
What is LFST's earnings track record?
Over the last 5 reported quarters with consensus data, LFST beat estimates 5 times (100%).
What is LFST's current P/E ratio and EPS?
LFST trades at a trailing P/E of 182.89 on trailing EPS of 0.05989970666005619 USD.
What do analysts rate LFST?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 11.8 USD.